BridgeBio Pharma (BBIO) Income from Continuing Operations (2018 - 2026)

BridgeBio Pharma has disclosed Income from Continuing Operations across 9 years of filings, most recently posting 112652000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 112652000.0, up 3.81% year-over-year; the trailing twelve-month figure through Mar 2026 was 676027000.0 (down 8.29% YoY), and the FY2025 annual result was 732938000.0, down 34.89% from the prior year.
• Income from Continuing Operations came in at 112652000.0 for Q1 2026 at BridgeBio Pharma, up from 194635000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 19053000.0 in Q1 2024 to a low of 267389000.0 in Q4 2024.
• The 5-year median for Income from Continuing Operations is 162179000.0 (2023), against an average of 151476117.65.
• Across the five-year window, Income from Continuing Operations soared 86.59% in 2024 and tumbled 514.64% in 2025, its largest moves.
• BridgeBio Pharma's Income from Continuing Operations stood at 145130000.0 in 2022, then slumped by 32.37% to 192106000.0 in 2023, then sank by 39.19% to 267389000.0 in 2024, then rose by 27.21% to 194635000.0 in 2025, then jumped by 42.12% to 112652000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 112652000.0 (Q1 2026), 194635000.0 (Q4 2025), and 184982000.0 (Q3 2025), per Business Quant data.